Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 4.63Zenith Drugs Ltd demonstrates a mixed financial performance. The company shows strength in solvency and profitability. However, liquidity, efficiency, and growth metrics are concerning. The company has low debt levels, indicating financial stability and reduced risk. Profitability ratios such as ROCE, ROE, and margins are strong, suggesting efficient operations and good earnings generation. Poor liquidity indicates potential difficulties in meeting short-term obligations. Inefficiency in asset utilization and a significant drop in revenue, operating profit, EPS, assets, and net income indicate the company is facing serious challenges. There is a moderate ability to cover interest and dividends. The company has poor EPS and book value per share, but manages capital expenditures reasonably well.
Health Score : 4.63Zenith Drugs Ltd demonstrates a mixed financial performance. The company shows strength in solvency and profitability. However, liquidity, efficiency, and growth metrics are concerning. The company has low debt levels, indicating financial stability and reduced risk. Profitability ratios such as ROCE, ROE, and margins are strong, suggesting efficient operations and good earnings generation. Poor liquidity indicates potential difficulties in meeting short-term obligations. Inefficiency in asset utilization and a significant drop in revenue, operating profit, EPS, assets, and net income indicate the company is facing serious challenges. There is a moderate ability to cover interest and dividends. The company has poor EPS and book value per share, but manages capital expenditures reasonably well.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
18.00
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
7.41
P/B RATIO
1.14
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
0.51
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
3.92
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹41.4 as on Sep 1, 2026.
Growth Score : 2.00The company's growth ratios are negative, indicating significant challenges. Declines in revenue, operating profit, EPS, assets, and net income suggest business contraction. This could reflect market challenges or internal operational issues. The negative growth rates raise concerns about the company's future prospects and sustainability. Focus needs to be on identifying the root causes of decline and implementing corrective strategies.
Revenue Growth RatePoorOperating Profit Growth RatePoorEarnings Per Share (EPS) GrowthPoorAsset Growth RatePoorNet Income Growth RatePoor| Growth Ratios | Mar 2023 | Mar 2024 |
|---|---|---|
| Revenue Growth Rate | 23.91 | 14.91 |
| Operating Profit Growth Rate | 28.57 | 88.89 |
| Earnings Per Share (EPS) Growth | ||
| Asset Growth Rate | 42.03 | 37.76 |
| Net Income Growth Rate | 66.67 | 100 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | PAR | 7.40 | 13.20 | Neutral | 17.00 | 10.65 | 13.00 |
| 2 | VAISHALI | 6.74 | 25.09 | Neutral | 4.00 | 0.31 | 4.00 |
| 3 | MONOPHARMA | 6.16 | 42.75 | Neutral | 4.00 | 0.20 | N/A |
| 4 | JFLLIFE | 6.07 | 10.88 | Neutral | 12.00 | 1.94 | 6.00 |
| 5 | QUESTLAB | 5.27 | 9.34 | Neutral | 18.00 | 9.16 | 15.00 |
| 6 | SOTAC | 5.27 | 17.25 | Neutral | 18.00 | 4.45 | 6.00 |
| 7 | ZENITHDRUG | 4.63 | 7.41 | Neutral | 17.00 | 2.30 | 10.00 |
| 8 | MANGALAM | 4.50 | -1.06 | Neutral | -15.00 | -27.68 | -44.00 |
| 9 | LASA | 4.39 | -2.61 | Highly Undervalued | -7.00 | -6.80 | -34.00 |
| 10 | KREBSBIO | 4.16 | -4.36 | Highly Undervalued | -4.00 | -7.85 | -4.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
No Stock News Available at This Moment.
Zenith Drugs Ltd. is an Indian pharmaceutical manufacturer specializing in generic and over-the-counter (OTC) drugs. The company manufactures and trades pharmaceutical formulations in various dosage forms like tablets, capsules, dry syrups, and liquid orals. It focuses on contract manufacturing and supplies to both domestic and international markets, primarily from its Indore-based facilities.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Zenith Drugs Ltd's P/E ratio (TTM) is 18, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Zenith Drugs Ltd's P/B ratio is 1.14, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Zenith Drugs Ltd's P/S ratio is 0.51, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Zenith Drugs Ltd's PEG ratio is N/A.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Zenith Drugs Ltd's EV/EBITDA ratio is 3.92.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Zenith Drugs Ltd's ROE is 16.13%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Zenith Drugs Ltd's ROA is 12.59%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Zenith Drugs Ltd's ROCE is 27%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Zenith Drugs Ltd's operating margin is 12.98%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Zenith Drugs Ltd's net margin is 7.63%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Zenith Drugs Ltd's current ratio is 1.87.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Zenith Drugs Ltd's debt-to-equity ratio is 0.14.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Zenith Drugs Ltd's interest coverage ratio is 5.33.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Zenith Drugs Ltd's DPS is ₹0.50.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Zenith Drugs Ltd's EPS is 6.47.
(Source line: "Ratios as of 01 Sept 2026, based on last traded price of ₹41.40. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2000
Headquarters: Indore, Madhya Pradesh
Core Offerings: Pharmaceutical Formulations, Contract Manufacturing, Domestic Sales, International Exports
Stock Listing: NSE (ZENITHDRUG), BSE ({bse})
Promoter: Bhardwaj and Soni Family
Zenith Drugs Limited was incorporated on January 14, 2000, in Indore, Madhya Pradesh. The company established itself as a manufacturer and trader of pharmaceutical formulations, primarily focusing on generic drugs. Over the years, it expanded its manufacturing capabilities and product portfolio, serving both the domestic Indian market and selected international regions. The company further strengthened its market presence by undertaking contract manufacturing for other pharmaceutical companies. A significant milestone was achieved in February 2024 when the company successfully launched its Initial Public Offering (IPO) on the NSE SME platform.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Manufactured Pharmaceutical Formulations | 88% (Approx.) | Not segmented by activity |
| Traded Pharmaceutical Formulations | 12% (Approx.) | Not segmented by activity |
Pharmaceutical Manufacturing: Zenith Drugs manufactures a diverse range of pharmaceutical formulations including tablets, capsules, liquid orals, and dry syrups, primarily for the generic drug market under its own brand.
Contract Manufacturing (CDMO): The company provides contract manufacturing services to other pharmaceutical entities, leveraging its WHO-GMP compliant manufacturing facilities.
Domestic & Export Sales: Products are distributed across various states in India, with a notable presence in Madhya Pradesh. The company also exports its formulations to a few international markets.
Pharmaceutical Trading: In addition to manufacturing, Zenith Drugs also engages in the trading of pharmaceutical formulations.
Mr. Sandeep Bhardwaj - Chairman & Managing Director. An experienced entrepreneur, he has been instrumental in guiding the company's strategic direction, operational efficiency, and overall growth in the pharmaceutical sector.
No major subsidiaries reported.
The company completed its Initial Public Offering (IPO) on the NSE SME platform in February 2024. No other major recent corporate actions on record.
The Zenith Drugs Ltd share price today is ₹41.40 on NSE (ZENITHDRUG), as of 13 Sept 2026.
As of 01 Sept 2026, Zenith Drugs Ltd share price is ₹41.40, with previous close ₹41.40. Today's range is ₹41.40 to ₹41.40. The 52-week range is ₹41.40 to ₹41.40.
As of today, Zenith Drugs Ltd's market cap is ₹66.65 crore (Small Cap).
Zenith Drugs Ltd's current P/E ratio is 18, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 26.80.
Zenith Drugs Ltd's current P/B ratio is 1.14.
Zenith Drugs Ltd's current dividend yield is 1.21%. Last dividend of ₹0.00 per share was declared on N/A.
Zenith Drugs Ltd's EPS (TTM) is ₹6.47.
Zenith Drugs Ltd. is an Indian pharmaceutical manufacturer specializing in generic and over-the-counter (OTC) drugs. The company manufactures and trades pharmaceutical formulations in various dosage forms like tablets, capsules, dry syrups, and liquid orals. It focuses on contract manufacturing and supplies to both domestic and international markets, primarily from its Indore-based facilities.
Zenith Drugs Ltd is promoted by Bhardwaj and Soni Family, holding 69.98% as of 01 Sept 2026.
Zenith Drugs Ltd is listed on NSE (ZENITHDRUG) and BSE ({bse}). Its next quarterly results are expected on July/August 2024 (Q1 FY25).
Adjusted Earnings Per Share (Adjusted EPS)